Argenx SE Shares Hit a Record High of €815.40
The Belgian immunology group's stock reaches a new all-time high during the session and continues its upward trajectory that began in the spring. Breaking through a closely watched technical threshold extends the bullish momentum observed for several weeks.
A Historical Record of €815.40 and a Resistance Breakthrough in Session
Argenx SE shares reached €815.40 during the session, a new all-time high surpassing the previous record of €815.20. The current price is €813.80, up 0.3% from the previous close of €811.40. The stock broke above its €813 resistance level during the session and remains above it. The long-term performance remains impressive: +31.1% over the quarter and +73.2% over the year, while the week remains nearly stable. The next round level identified is at €820, with no previous technical reference above.
Indicators confirm the strength of the underlying movement. The price is 5.77% above the MM20 (€769.40), 12.90% above the MM50 (€720.81), and nearly 16% above the MM200 (€702.55), a configuration that reflects a bullish trend across the three horizons. The RSI at 62 remains in a neutral zone despite the new peak, without yet signaling any excess. The one-month volatility at 9.5 remains contained considering the amplitude of the quarterly rally.
Stretched Valuation Driven by VYVGART's Commercial Dynamics
According to the consensus of analysts, the stock is trading at approximately 35.4 times the earnings expected for the current fiscal year and 27.1 times those of the following year. This high multiple reflects the growth expectations associated with the Belgian group's portfolio, with efgartigimod, marketed under the brand VYVGART, remaining the commercial powerhouse. The publication of long-term data in myositis and Sjögren's syndrome, presented at the EULAR congress in early June, had already fueled market interest in the extension of therapeutic indications.
The group had also reported in early May a doubling of net profit in the first quarter of 2026 and a 63% increase in VYVGART sales. This growth base partly explains the stock's trajectory observed since March. In the short term, the stock's behavior around the €820 level will be the benchmark to watch, in a context where all moving averages remain upward-oriented.
